Ultra-sensitive Analysis of Disease Protein Biomarker by Single-molecule Affinity Nanomicroscopy

Porath Danny, HUJI, Faculty of Science, The Institute of Chemistry
FRIEDLER Assaf, HUJI, Faculty of Science, The Institute of Chemistry

New Ultra-Sensitive Cancer and Other Diseases Biomarker Detection Based on Single Molecule Imaging


Biomarker, Cancer, Single molecule imaging, Electron microscopy

Development Stage

proof of concept; ongoing research

Patent Status

Provisional patent application filed


The biomarkers market was just over 13 billion dollars in 2011 and it is expected to double by 2016.


Our Innovation

  • We are developing an ultra sensitive and affordable integrated biomarkers detection platform that combines functionalized nanoparticles
  • The new technology is based on a single molecule imaging technique that is relatively cheap and simple to operate with 100-1000 fold superior sensitivity than the common detection methods used today.
  • The method is based on binding of a biomarker to nanoparticles- antibodies conjugates, followed by their detection and characterization with electron microscope.
  • This method allows multiplex biomarker detection for personalized diagnostics, thus enabling high detection confidence and parallel diseases recognition.
  • The platform proposed here allows the detection of the biomarkers using the new generation of electron microscopes (known as desktop EM) with a 10,000’s USD price tag and automation capability. With the miniaturization and software development progressing rapidly, we'll probably see additional drop in the microscopes price that will make them even more appealing.  

Key Features

  • The method is free of amplification steps  required by standard methods and therefore is not dependent on relatively sensitive enzymatic processes.
  • Antibodies bound to NPs have better accessibility to the target molecules in solution compared to antibodies that are attached to a surface that are in use in other detection methods.  
  • Using NPs with different sizes or compositions allows detection of various biomarkers at the same sample (multiplexing).

Development Milestones

Seeking funding for ongoing research and industrial collaboration,

The Opportunity

  • We are offering an innovative platform technology that may revolutionize early stage diagnostics of disease states.
  • Biomarker market was just over 13 billion dollars in 2011 and it is expected to almost double by 2016. This growth is primarily attributed to its application in various fields such as drug discovery and development, personalized medicine, and molecular diagnostics.


Researcher Information






Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
Contact ME: